Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $1.697M Beat $800.000K Estimate
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM - Slideshow
Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.